Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of Fenticonazole Nitrate Vaginal Capsules for the Treatment of Vulvovaginal Candidiasis (VVC) under the brand name Fenticad™.
In a commitment to further strengthening the women’s healthcare portfolio Cadila’s Fenticad™ will be 35% more cost-effective and a drug of choice. Fenticad™ will be made available in 600 mg tablets.
VVC affects up to 75% of women once in their lifetime and severely impacts their quality of life. Almost 37% of women in rural India suffers from VVC in their reproductive age.*
Itching (pruritus) and increased vaginal discharge are the most typical symptoms. Other symptoms are variable: soreness and burning, painful sexual intercourse (dyspareunia), or discomfort passing urine (dysuria). These symptoms may also occur in other vaginal infections.
A recent dipstick survey revealed that 36% of women went into social isolation when they were having VVC and 33% women admitted that symptoms of VVC impacted their self-confidence (Data on file).
Diabetes, pregnancy, inadequate intimate hygiene, unprotected and intense sexual activity, and antibiotic treatment can lead to high risk of developing VVC.
During pregnancy, topical anti- fungal treatment (such as fenticonazole, clotrimazole, fluconazole) with the preparation of vaginal capsule or cream is preferred.
Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies in India.
It has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world.
Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.
*Int.J.Curr.Microbiol.App.Sci (2015) 4(8): 253-266